Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) rejects an undervalued takeover bid from Amgen Inc

Boston, MA 02/07/2013 (wallstreetpr) – Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) recently rejected an undervalued takeover bid from Amgen Inc., fixed at $120 per share. However, the biopharmaceutical company also announced that it is currently exploring the strategic alternative of selling itself to other bidders who would offer a higher price for the company. This announcement made […]